Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Atlas Venture
AddedFeb 11, 2024
UpdatedJul 2, 2026
Atlas Venture

Atlas Venture

Operating

Atlas Ventures LLC: A US-based venture capital firm investing in early-stage tech and life science startups.

Location
Cambridge, MA, US
Founded
1980
Firm
Compare
Portfolio
Fundraising
Employees
Website

Atlas Venture is a US-based venture capital firm specializing in early-stage investments in technology and life science companies. The firm typically participates in Seed, Series A, and Series B rounds, supporting startups with significant potential for innovation and growth. Atlas Venture's focus is on translating groundbreaking science into life-changing medicines, partnering with top-tier life science entrepreneurs to create and build breakthrough biotech companies.

Notable portfolio companies include Alnylam Pharmaceuticals, DraftKings, Intellia Therapeutics, and PillPack. Key partners at Atlas Venture bring extensive industry experience and have been affiliated with successful ventures across the biotech and tech sectors. The firm's investment philosophy centers on fostering deep collaborations with entrepreneurs to drive impactful advancements. Atlas Venture also offers unique value-add services, including strategic guidance, operational support, and access to a robust network of industry experts and resources.

Atlas Venture - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments193
Current Portfolio Count80
Total Portfolio Exits18

Top Investment Stages

Series A57 (33.1%)
Seed46 (26.7%)
Series B44 (25.6%)
Series C14 (8.1%)
Series Unknown11 (6.4%)

Stage Mix

Series A 33%Seed 27%Series B 26%Series C 8%Series Unknown 6%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Triveni Bio logo

Triveni Bio

Accent Therapeutics logo

Accent Therapeutics

Comanche Biopharma logo

Comanche Biopharma

Remix Therapeutics logo

Remix Therapeutics

Aiolos Bio logo

Aiolos Bio

Nvelop Therapeutics logo

Nvelop Therapeutics

Nimbus Therapeutics logo

Nimbus Therapeutics

K36 Therapeutics logo

K36 Therapeutics

Right-Hand Cybersecurity logo

Right-Hand Cybersecurity

Chroma Medicine logo

Chroma Medicine

Sionna Therapeutics logo

Sionna Therapeutics

Be Biopharma logo

Be Biopharma

Triana Biomedicines logo

Triana Biomedicines

Arkuda Therapeutics logo

Arkuda Therapeutics

Korro Bio logo

Korro Bio

Curie Therapeutics logo

Curie Therapeutics

HotSpot Therapeutics logo

HotSpot Therapeutics

Matchpoint Therapeutics logo

Matchpoint Therapeutics

Rectify Pharmaceuticals logo

Rectify Pharmaceuticals

Obsidian Therapeutics logo

Obsidian Therapeutics

Affinia Therapeutics logo

Affinia Therapeutics

Scorpion Therapeutics logo

Scorpion Therapeutics

ImageneBio logo

ImageneBio

Kinaset Therapeutics logo

Kinaset Therapeutics

Q32 Bio logo

Q32 Bio

Atlas Venture - Similar Investment Firms

Kleiner Perkins Caufield & Byers logo

Kleiner Perkins Caufield & Byers

kleinerperkins.com

Battery Ventures logo

Battery Ventures

battery.com

Two Sigma Ventures logo

Two Sigma Ventures

Summit Partners logo

Summit Partners

summitpartners.com

Atlas Peak Capital logo

Atlas Peak Capital

General Atlantic logo

General Atlantic

Primary Venture Partners logo

Primary Venture Partners

primary.vc

Advent Venture Partners logo

Advent Venture Partners

Alumni Ventures logo

Alumni Ventures

av.vc

LifeSci Venture Partners logo

LifeSci Venture Partners

lifesciventure.com

Voyager Capital logo

Voyager Capital

voyagercapital.com

Navigator Technology Ventures logo

Navigator Technology Ventures

Triangle Peak Partners logo

Triangle Peak Partners

Precursor Ventures logo

Precursor Ventures

precursorvc.com

Cross Atlantic Ventures logo

Cross Atlantic Ventures

Atlas Venture - Classification

Also Known As
  • Atlas Venture, Inc.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end